SCHEMBL2992384

SCHEMBL2992384

CN1CCN(c2cc[c]c(C3=CCCCC3)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.41
KIT P10721 1/20 0.41
PSMB5 P28074 2/20 0.39
PSMB1 P20618 1/20 0.39
ADRA2C P18825 2/20 0.38
HTR3A P46098 1/20 0.37
GAA P10253 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 2/20 0.36
PTK2B Q14289 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
HRH4 Q9H3N8 3/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GLA P06280 1/20 0.35
CHKA P35790 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17667850 0.79 CHKA (0.44) KDM4ECHKANCF1
SCHEMBL4982315 0.79 CSF1R (0.43) CSF1RADRA2CHTR3AGAAKDM4E
SCHEMBL3080128 0.73 MAPT (0.52) CSF1RKITPSMB5PSMB1ADRA2C
SCHEMBL3587531 0.73 ADRA2C (0.49) ADRA2CHTR3AGAAKDM4EMAPT
SCHEMBL4101892 0.70 HRH4 (0.47) ADRA2CHTR3AGAAKDM4EHRH4
SCHEMBL4984976 0.70 HRH4 (0.41) ADRA2CHTR3AGAAKDM4EMAPT
SCHEMBL5884761 0.70 HTR3A (0.51) ADRA2CHTR3AGAAKDM4EMAPT
SCHEMBL15400291 0.69 MAPT (0.40) CSF1RADRA2CHTR3AGAAKDM4E
SCHEMBL2935698 0.69 SIRT6 (0.56) CSF1RKITMAPTMAPK1ALDH1A1
SCHEMBL2912399 0.69 CSF1R (0.54) CSF1RKITPSMB5PSMB1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222298-A1 USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER Janssen Pharmaceutica N.V. (BE) 2010-09-01 EP disclosed
WO-2009058801-A1 USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-07 WO disclosed